RxDoctor Payments Data

Miranda Horton, MD

Internal Medicine · Greenville, SCNPI 1013930700

Payments from drug & device makers

$6,632in general payments, 2019–2025

Across 422 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$969
  • Pfizer$605
  • Lilly USA, LLC$417
  • Boehringer Ingelheim$404
  • Abbott$398
  • Amgen$378
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,628100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,632 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$149,500
Medicare patients
219
Services billed
2,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$88,309
JardianceEmpagliflozin50$68,044
EliquisApixaban45$48,626
XareltoRivaroxaban33$37,274
MounjaroTirzepatide19$26,849
JanuviaSitagliptin Phosphate20$21,692
MyrbetriqMirabegron29$15,995
FarxigaDapagliflozin Propanediol13$15,804
LinzessLinaclotide17$11,442
Janumet XrSitagliptin Phos/Metformin Hcl16$10,890
MultaqDronedarone Hcl12$8,969
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$8,881
Tresiba Flextouch U-100Insulin Degludec11$6,463
BelsomraSuvorexant12$5,607
DayvigoLemborexant13$4,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$969$88,30956 claims
Boehringer IngelheimJardiance$404$68,04450 claims
PfizerEliquis$605$48,62645 claims
MerckJanuvia, Janumet Xr, Belsomra$116$38,18848 claims
Johnson & JohnsonXarelto$42$37,27433 claims
Lilly USA, LLCMounjaro$417$26,84919 claims
Astellas Pharma US IncMyrbetriq$226$15,99529 claims
AstraZenecaFarxiga$330$15,80413 claims
AbbVieLinzess, Synthroid$245$15,30948 claims
Sanofi-aventis U.S. LLCMultaq$301$8,96912 claims
Eisai Inc.Dayvigo$69$4,09913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →